Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DEX-SSBAP30-FA is a **folate (FA)-conjugated, disulfide-based cationic dextran polymer** designed for targeted **gene delivery**, particularly to cancer cells overexpressing folate receptors such as SKOV-3 ovarian cancer cells[1][5]. The formulation exploits a high density of primary amine side groups for effective DNA binding and in vivo delivery. The FA-conjugation confers tumor-targeting capability via folate receptor-mediated endocytosis. In preclinical models, DEX-SSBAP30-FA demonstrated efficient gene transfer by intravenous injection, low cytotoxicity, and improved tumor targeting compared to non-FA-conjugated analogs and performance comparable to established polymeric gene delivery vectors like linear polyethylenimine[1][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on DEX-SSBAP30-FA.